RESUMEN
Background: Non-alcoholic fatty liver disease [NAFLD] is the most common chronic liver disease that exposes patients to a great risk of emerging cardiovascular diseases and could develop to cirrhosis or hepatocellular carcinoma if left unmanaged
Objective of the Study: this article is intended to provide an overview and explore the optimal intervention for management of NAFLD in the short and long term
Methods: Electronic search in the scientific database from 1966 to 2017 [Medline, Embase, the Cochrane Library as well as NHS center websites were searched for English Publications were obtained from both reprint requests and by searching the database. Data extracted included authors, country, year of publication, age and sex of patients, epidemiology, geographical distribution, pathophysiology, risk factors, clinical manifestations, investigations and types of surgical treatment
Conclusion: It was concluded from the extensive review of the literature that Lifestyle modification including diet, physical activity and controlling metabolic disorders are the cornerstone in current management of NAFLD. Nevertheless, Insulin-sensitizing agents and antioxidants, particularly thiazolidinediones and vitamin E, seem to be a very promising pharmacologic treatment for non-alcoholic steatohepatitis, yet further long-term multicenter studies need to be conducted for confirmation and assessment
RESUMEN
Anticoagulation is the mainstay treatment of pulmonary embolism. Using low molecular weight heparin versus unfractionated heparin remains a matter of debate
Objectives: the aim of this review is to study the prognosis of using low molecular weight versus unfractionated heparin in treatment of pulmonary embolism
Methods: pubMed and Cochrane library were searched for articles comparing the efficacy of low molecular weight heparin and unfractionated heparin in management of pulmonary embolism. Ten related results were selected for review
Results: literatures studies indicated that low molecular weight heparin was effective in therapeutic treatment of acute sub-massive and massive pulmonary embolism. It was as effective as intravenous unfractionated heparin. It was not associated with higher risk of major, minor bleeding, or thrombocytopenia. Low molecular weight heparin was as effective as unfractionated heparin in prophylaxis of deep venous sinus thrombosis as well as pulmonary embolism
Discussion: low-molecular-weight heparin seemed to be as effective safe as intravenous unfractionated heparin for the treatment as well as prophylaxis of pulmonary embolism. It was also safe with no major bleeding risk or higher risk of thrombocytopenia
Conclusion: both low molecular weight and unfractionated heparin had similar efficacy and safety in management of PE